S&P 500   5,081.63 (+0.23%)
DOW   38,898.63 (-0.13%)
QQQ   437.93 (+0.61%)
AAPL   180.03 (-0.77%)
MSFT   409.55 (+0.45%)
META   489.05 (+1.04%)
GOOGL   137.24 (+0.63%)
AMZN   174.95 (+1.03%)
TSLA   199.87 (-1.07%)
NVDA   792.80 (+2.08%)
NIO   5.67 (+4.42%)
AMD   190.45 (+7.88%)
BABA   74.06 (-0.71%)
T   16.99 (+0.18%)
F   12.40 (+0.81%)
MU   89.85 (+0.16%)
CGC   3.27 (-2.68%)
GE   156.02 (+0.26%)
DIS   111.23 (+0.39%)
AMC   4.29 (-14.03%)
PFE   26.77 (-1.00%)
PYPL   60.23 (-0.03%)
XOM   104.55 (+0.22%)
S&P 500   5,081.63 (+0.23%)
DOW   38,898.63 (-0.13%)
QQQ   437.93 (+0.61%)
AAPL   180.03 (-0.77%)
MSFT   409.55 (+0.45%)
META   489.05 (+1.04%)
GOOGL   137.24 (+0.63%)
AMZN   174.95 (+1.03%)
TSLA   199.87 (-1.07%)
NVDA   792.80 (+2.08%)
NIO   5.67 (+4.42%)
AMD   190.45 (+7.88%)
BABA   74.06 (-0.71%)
T   16.99 (+0.18%)
F   12.40 (+0.81%)
MU   89.85 (+0.16%)
CGC   3.27 (-2.68%)
GE   156.02 (+0.26%)
DIS   111.23 (+0.39%)
AMC   4.29 (-14.03%)
PFE   26.77 (-1.00%)
PYPL   60.23 (-0.03%)
XOM   104.55 (+0.22%)
S&P 500   5,081.63 (+0.23%)
DOW   38,898.63 (-0.13%)
QQQ   437.93 (+0.61%)
AAPL   180.03 (-0.77%)
MSFT   409.55 (+0.45%)
META   489.05 (+1.04%)
GOOGL   137.24 (+0.63%)
AMZN   174.95 (+1.03%)
TSLA   199.87 (-1.07%)
NVDA   792.80 (+2.08%)
NIO   5.67 (+4.42%)
AMD   190.45 (+7.88%)
BABA   74.06 (-0.71%)
T   16.99 (+0.18%)
F   12.40 (+0.81%)
MU   89.85 (+0.16%)
CGC   3.27 (-2.68%)
GE   156.02 (+0.26%)
DIS   111.23 (+0.39%)
AMC   4.29 (-14.03%)
PFE   26.77 (-1.00%)
PYPL   60.23 (-0.03%)
XOM   104.55 (+0.22%)
S&P 500   5,081.63 (+0.23%)
DOW   38,898.63 (-0.13%)
QQQ   437.93 (+0.61%)
AAPL   180.03 (-0.77%)
MSFT   409.55 (+0.45%)
META   489.05 (+1.04%)
GOOGL   137.24 (+0.63%)
AMZN   174.95 (+1.03%)
TSLA   199.87 (-1.07%)
NVDA   792.80 (+2.08%)
NIO   5.67 (+4.42%)
AMD   190.45 (+7.88%)
BABA   74.06 (-0.71%)
T   16.99 (+0.18%)
F   12.40 (+0.81%)
MU   89.85 (+0.16%)
CGC   3.27 (-2.68%)
GE   156.02 (+0.26%)
DIS   111.23 (+0.39%)
AMC   4.29 (-14.03%)
PFE   26.77 (-1.00%)
PYPL   60.23 (-0.03%)
XOM   104.55 (+0.22%)

Legend Biotech (LEGN) Stock Forecast & Price Target

$65.71
-2.07 (-3.05%)
(As of 02:27 PM ET)

Legend Biotech Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 11 Analyst Ratings

Analysts' Consensus Price Target

$82.41
25.41% Upside
High Forecast$94.00
Average Forecast$82.41
Low Forecast$64.00
TypeCurrent Forecast
3/1/23 to 2/29/24
1 Month Ago
1/30/23 to 1/30/24
3 Months Ago
12/1/22 to 12/1/23
1 Year Ago
3/1/22 to 3/1/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
11 Buy rating(s)
9 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$82.41$82.41$82.01$70.14
Predicted Upside25.41% Upside28.72% Upside30.50% Upside35.43% Upside
Get Legend Biotech Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for LEGN and its competitors with MarketBeat's FREE daily newsletter.


LEGN Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LEGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Legend Biotech Stock vs. The Competition

TypeLegend BiotechMedical CompaniesS&P 500
Consensus Rating Score
2.82
2.68
2.48
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside19.00% Upside1,855.40% Upside7.87% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/24/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$93.00 ➝ $94.00+56.41%
12/22/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$87.00+44.90%
12/19/2023Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSector Perform$65.00+4.75%
11/6/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$90.09+36.56%
8/2/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
7/20/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$65.00 ➝ $85.00+13.11%
6/12/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$85.00 ➝ $90.00+31.79%
5/25/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Corwin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$64.00-3.09%
5/22/2023Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
5/19/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$74.00 ➝ $83.00+18.42%
4/25/2023BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$79.00 ➝ $90.00+32.24%
4/19/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$65.00 ➝ $76.00+21.60%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:53 PM ET.












LEGN Price Target - Frequently Asked Questions

What is Legend Biotech's consensus rating and price target?

According to the issued ratings of 11 analysts in the last year, the consensus rating for Legend Biotech stock is Moderate Buy based on the current 2 hold ratings and 9 buy ratings for LEGN. The average twelve-month price prediction for Legend Biotech is $82.41 with a high price target of $94.00 and a low price target of $64.00. Learn more on LEGN's analyst rating history.

Do Wall Street analysts like Legend Biotech more than its competitors?

Analysts like Legend Biotech more than other Medical companies. The consensus rating score for Legend Biotech is 2.82 while the average consensus rating score for medical companies is 2.68. Learn more on how LEGN compares to other companies.

Does Legend Biotech's stock price have much upside?

According to analysts, Legend Biotech's stock has a predicted upside of 28.72% based on their 12-month stock forecasts.

What analysts cover Legend Biotech?

Legend Biotech has been rated by Barclays, HC Wainwright, and Scotiabank in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:LEGN) was last updated on 2/29/2024 by MarketBeat.com Staff